Lung-Specific mRNA Delivery Enabled by Sulfonium Lipid Nanoparticles

Area of Science:

• Biotechnology
• Nanomedicine
• Drug Delivery Systems

Background:

• Lipid nanoparticles (LNPs) are the leading mRNA carriers, primarily targeting liver diseases in clinical trials.
• Unlocking mRNA therapy's full potential requires LNP systems targeting organs beyond the liver.
• Developing safe and effective extrahepatic LNP delivery systems is crucial for broader mRNA therapeutic applications.

Purpose of the Study:

• To develop novel sulfonium lipid nanoparticles (sLNPs) for targeted systemic mRNA delivery to the lungs.
• To evaluate the safety and efficacy of sLNPs for lung-specific mRNA delivery in vivo.

Main Methods:

• Development of novel sulfonium lipid nanoparticles (sLNPs).
• Intravenous administration of sLNPs carrying mRNA in a mouse model.
• Assessment of mRNA distribution, lung targeting specificity, and systemic toxicity, including inflammation and organ damage.

Main Results:

• sLNPs demonstrated effective and specific mRNA delivery to the lungs after intravenous injection in mice.
• No significant lung or systemic inflammation was observed.
• No signs of toxicity were detected in major organs, indicating a favorable safety profile.

Conclusions:

• The newly developed lung-specific sLNP platform is both safe and efficacious for systemic mRNA delivery.
• sLNPs hold significant promise for advancing mRNA-based therapies for lung-associated diseases.
• This novel LNP system opens new avenues for treating various pulmonary conditions using mRNA technology.